© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Metagenomi, Inc. Common Stock (MGX) stock declined over -1.31%, trading at $1.51 on NASDAQ, down from the previous close of $1.53. The stock opened at $1.47, fluctuating between $1.46 and $1.53 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 03, 2026 | 1.47 | 1.53 | 1.46 | 1.51 | 170.97K |
| Mar 02, 2026 | 1.46 | 1.62 | 1.46 | 1.53 | 222.32K |
| Feb 27, 2026 | 1.57 | 1.58 | 1.48 | 1.52 | 235.86K |
| Feb 26, 2026 | 1.57 | 1.61 | 1.53 | 1.60 | 82.9K |
| Feb 25, 2026 | 1.49 | 1.56 | 1.49 | 1.55 | 135.73K |
| Feb 24, 2026 | 1.41 | 1.52 | 1.41 | 1.50 | 145.62K |
| Feb 23, 2026 | 1.48 | 1.50 | 1.41 | 1.41 | 285.54K |
| Feb 20, 2026 | 1.50 | 1.51 | 1.46 | 1.46 | 136.34K |
| Feb 19, 2026 | 1.46 | 1.54 | 1.44 | 1.52 | 249.24K |
| Feb 18, 2026 | 1.44 | 1.50 | 1.44 | 1.47 | 129.12K |
| Feb 17, 2026 | 1.45 | 1.52 | 1.42 | 1.46 | 161.47K |
| Feb 13, 2026 | 1.46 | 1.51 | 1.45 | 1.46 | 199.27K |
| Feb 12, 2026 | 1.52 | 1.54 | 1.44 | 1.45 | 258.28K |
| Feb 11, 2026 | 1.58 | 1.59 | 1.49 | 1.52 | 156.78K |
| Feb 10, 2026 | 1.53 | 1.59 | 1.52 | 1.57 | 314.99K |
| Feb 09, 2026 | 1.54 | 1.55 | 1.45 | 1.53 | 265.9K |
| Feb 06, 2026 | 1.46 | 1.55 | 1.39 | 1.54 | 443.83K |
| Feb 05, 2026 | 1.45 | 1.57 | 1.40 | 1.41 | 586.05K |
| Feb 04, 2026 | 1.49 | 1.50 | 1.44 | 1.45 | 348.44K |
| Feb 03, 2026 | 1.54 | 1.56 | 1.46 | 1.49 | 272.5K |
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
| Employees | 202 |
| Beta | 0.52 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 28.145% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |